The Eastern European Cardiovascular Market Outlook to 2010

Table of Contents

Executive Summary

Patient potential

Regional healthcare and licensing

Regional market analysis

Key players in the Eastern European cardiovascular market

Chapter 1 Patient potential

Summary

Introduction

Disease description

Defining patient potential

Limitations of cardiovascular epidemiology data

Cardiovascular risk factors

Hypertension

Prevalence

Factors driving prevalence

Forecast prevalence

Dyslipidemia

Prevalence

Factors driving prevalence

Forecast prevalence

Diabetes

Prevalence

Forecast prevalence

Cardiovascular disease

Prevalence

Acute thrombotic events

Acute coronary syndromes

Venous thromboembolism

Stroke

Chapter 2 Regional healthcare and licensing trends

Summary

Introduction

Regional healthcare expenditure

Healthcare financing

The external environment

Licensing analysis

Chapter 3 Regional market analysis

Summary

Introduction

Market breakdown by therapeutic area

Leading products

Market breakdown by country

Anti-hypertensives

Introduction

Analysis of the top 10 anti-hypertensives

Hypertension class sales by country, 2004

Market analysis by drug class

ACE inhibitors

Calcium channel blockers

Beta blockers

Other major classes of drugs

Anti-hypertensives sales forecasts

Dyslipidemia

Introduction

Analysis of the top 10 anti-dyslipidemics

Dyslipidemia sales by country, 2004

Market analysis by drug class

Statins

Fibrates

Anti-dyslipidemics sales forecasts

Thrombosis

Introduction

Analysis of the top 10 anti-thrombotics

Market analysis by drug class

Heparins/ low molecular weight heparins

Anti-platelets

Vitamin K antagonists

Other anti-thrombotics

Anti-thrombotics sales forecasts

Cardiac therapies

Introduction

Analysis of the top 10 cardiac therapies

Market analysis by drug class

Nitrites/Nitrates

Anti-arrhythmics

Other cardiac therapy drugs

Chapter 4 Key players in the Eastern European cardiovascular market

Summary

Introduction

Eastern European market shares

Servier

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Sanofi-Aventis

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Pfizer

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Novartis

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Krka

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Zentiva

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Gedeon Richter

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Merck & Co.

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Chapter 5 Appendix

IMS sales data

Glossary

Index

List of Figures

Figure 1.1: Relationship between cardiovascular disease and risk factors

Figure 1.2: Risk factors associated with hypertension

Figure 1.3: Estimated prevalence of obesity in twelve Eastern European market, 2005 and 2010

Figure 2.4: External analysis of the Eastern European region

Figure 3.5: Competitive dynamics in the Eastern European cardiovascular market, 2003.04

Figure 3.6: Competitive dynamics in the global anti-hypertensives market by drug class, 2003.

Figure 3.7: Competitive dynamics of leading Eastern European anti-hypertensives by leading brands, 2004

Figure 3.8: Competitive dynamics in the Eastern European anti-dyslipidemic market by drug 2003.04

Figure 3.9: Competitive dynamics of the top ten anti-dyslipidemic by drug class, 2004

Figure 3.10: Competitive dynamics in the Eastern European anti-thrombotic market by drug class, 2003.04

Figure 3.11: Competitive dynamics of the top ten anti-thrombotics in the Eastern European market by drug class, 2004

Figure 3.12: Competitive dynamics in the Eastern European cardiac therapy market by drug class, 2003.04

Figure 3.13: Competitive dynamics of the top ten cardiac therapy by drug class, 2004

Figure 4.14: Market share of key players in the Eastern European cardiovascular market, 2000 2004 List of

Tables

Table 1.1: Estimated prevalence of hypertension in twelve Eastern European markets, 2004

Table 1.2: Estimated prevalence of hypertension in twelve Eastern European markets, 2005.

Table 1.3: Estimated prevalence of dyslipidemia in twelve Eastern European markets, 2004

Table 1.4: Estimated prevalence of dyslipidemia in twelve Eastern European markets, 2005.

Table 1.5: Estimated prevalence of diabetes in twelve Eastern European markets, 2004

Table 1.6: Estimated prevalence of diabetes in twelve Eastern European markets, 2005.10

Table 1.7: Estimated prevalence of major cardiovascular diseases in the Eastern European market, 2004

Table 1.8: Estimated incidence of ACS in the Eastern European market, 2004

Table 1.9: Estimated incidence of VTE in the Eastern European market, 2004

Table 1.10: Prevalence of stroke in twelve Eastern European markets, 2004

Table 2.11: Recent statistics on healthcare sector in twelve Eastern European markets, 2002

Table 2.12: Public and private financing in twelve Eastern European markets, 2002

Table 2.13: Sales of types of cardiovascular brands in the Eastern European pharmaceutical market, 2000-04

Table 2.14: Sales of types of cardiovascular brands in twelve Eastern European markets, 2004

Table 3.15: Breakdown of Eastern European cardiovascular market by major therapeutic area, 2000.04

Table 3.16: Top 10 cardiovascular products in the Eastern European market, 2004

Table 3.17: Cardiovascular sales across twelve Eastern European markets, 2004

Table 3.18: Breakdown of Eastern European anti-hypertensives market by drug class, 2000.04

Table 3.19: Competitive dynamics of the Eastern European anti-hypertensives market by leading brands, 2004

Table 3.20: Market share of the leading classes of the anti-hypertensives in twelve Eastern European markets, 2004

Table 3.21: Breakdown of the ACE inhibitor market in the Eastern European market by leading brands, 2003.04

Table 3.22: Breakdown of the global CCB market by leading brands, 2003.04

Table 3.23: Breakdown of the Eastern European beta-blocker market by leading brands, 2003.

Table 3.24: Breakdown of the performance of drugs outside the major classes in the Eastern European market by leading brands, 2003.04

Table 3.25: Sales forecasts for drug classes within the Eastern European anti-hypertensives market, 2004.10

Table 3.26: Breakdown of the Eastern European anti-dyslipidemics market by drug class, 2000.

Table 3.27: Breakdown of Eastern European anti-dyslipidemic market by leading brands, 2004

Table 3.28: Anti-dyslipidemics market share in twelve Eastern European markets, 2004

Table 3.29: Sales forecasts for drug classes within the Eastern European anti-dyslipidemics market, 2004.10

Table 3.30: Breakdown of Eastern European anti-thrombotic market by drug class, 2000.04

Table 3.31: Breakdown of Eastern European anti-thrombotic market by leading brands, 2004

Table 3.32: Sales forecasts for drug classes within the Eastern European anti-thrombotics market, 2004.10

Table 3.33: Breakdown of Eastern European cardiac therapy market by drug class, 2000.04

Table 3.34: Breakdown of the Eastern European cardiac therapy market by leading brands, 2004

Table 4.35: Key players in the Eastern European cardiovascular market, 2000.2004

Table 4.36: Servier s marketed cardiovascular portfolio, 2003-04

Table 4.37: Servier s cardiovascular R&D pipeline, 2005

Table 4.38: Forecast sales for Servier s cardiovascular portfolio, 2004.10

Table 4.39: Sanofi-Aventis  marketed cardiovascular portfolio, 2003-04

Table 4.40: Sanofi-Aventis  cardiovascular R&D pipeline, 2005

Table 4.41: Forecast sales for Sanofi-Aventis  cardiovascular portfolio, 2004-10

Table 4.42: Pfizer s marketed cardiovascular portfolio in Eastern European market, 2003-04

Table 4.43: Pfizer s cardiovascular R&D pipeline, 2005

Table 4.44: Forecast sales for Pfizer s Eastern European cardiovascular portfolio, 2004.10

Table 4.45: Novartis  marketed cardiovascular portfolio, 2003-04

Table 4.46: Novartis  cardiovascular R&D pipeline, 2005

Table 4.47: Forecast sales for Novartis s cardiovascular portfolio, 2004.10

Table 4.48: Krka s marketed cardiovascular portfolio, 2003-04

Table 4.49: Forecast sales for Krka s cardiovascular portfolio, 2004.10

Table 4.50: Zentiva s marketed cardiovascular portfolio, 2003-04

Table 4.51: Forecast sales for Zentiva s cardiovascular portfolio, 2004.10

Table 4.52: Gedeon Richter s marketed cardiovascular portfolio, 2003-04

Table 4.53: Forecast sales for Gedeon Richter s cardiovascular portfolio, 2004.10

Table 4.54: Merck & Co s marketed cardiovascular portfolio, 2003-04

Table 4.55: Merck & Co s cardiovascular R&D pipeline, 2005

Table 4.56: Forecast sales for Merck & Co s cardiovascular portfolio, 2004.10